You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

Therapy with ASA, P2Y12 inhibitor, and statin at discharge following PCI in eligible patients

Patients undergoing PCI who receive prescriptions for all medications (ASA, P2Y12 and statins) for which they are eligible for at discharge

Date Reviewed: November 7, 2015

Measure Info

NQF 0964NQF EndorsedCQMC Core Measure
Measure Type: 
Composite
Measure Steward: 
American College of Cardiology
Clinical Topic Area: 
Interventional Cardiology

Care Setting: 
Inpatient
Outpatient
Data Source: 
Registry

ACP supports this measure because it considers pre-existing medications, includes appropriate exclusion criteria for patients without stents, and its use of electronic medical records reduces provider burden.

As part of an ongoing effort to improve user experience, we have made some updates to the Performance Measures section of ACP. Tell us what you think!